VINC - Vincerx Pharma, Inc.

0.1
-0.033   -33.300%

Share volume: 4,482,550
Last Updated: 04-22-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$0.13
-0.03
-0.25%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 31%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
-88.05%
2 Year
-98.64%
Key data
Stock price
$0.10
P/E Ratio 
0.00
DAY RANGE
$0.08 - $0.13
EPS 
-$6.26
52 WEEK RANGE
$0.08 - $1.22
52 WEEK CHANGE
-$87.95
MARKET CAP 
2.771 M
YIELD 
N/A
SHARES OUTSTANDING 
5.234 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-28-2025
NEXT EARNINGS DATE
05-13-2025
BETA 
0.80
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Ahmed M. Hamdy
Region: US
Website: vincerx.com
Employees: 60
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Vincerx Pharma, Inc. researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors.

Recent news